IDYA
Price
$21.10
Change
-$0.00 (-0.00%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
1.85B
68 days until earnings call
XENE
Price
$30.70
Change
+$0.24 (+0.79%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
2.36B
63 days until earnings call
Interact to see
Advertisement

IDYA vs XENE

Header iconIDYA vs XENE Comparison
Open Charts IDYA vs XENEBanner chart's image
IDEAYA Biosciences
Price$21.10
Change-$0.00 (-0.00%)
Volume$15.76K
Capitalization1.85B
Xenon Pharmaceuticals
Price$30.70
Change+$0.24 (+0.79%)
Volume$5.62K
Capitalization2.36B
IDYA vs XENE Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. XENE commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (IDYA: $21.08 vs. XENE: $30.70)
Brand notoriety: IDYA and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 45% vs. XENE: 56%
Market capitalization -- IDYA: $1.85B vs. XENE: $2.36B
IDYA [@Biotechnology] is valued at $1.85B. XENE’s [@Biotechnology] market capitalization is $2.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 6 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 6 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than XENE.

Price Growth

IDYA (@Biotechnology) experienced а +5.14% price change this week, while XENE (@Biotechnology) price change was +5.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.36B) has a higher market cap than IDYA($1.85B). IDYA YTD gains are higher at: -17.899 vs. XENE (-22.296). XENE has higher annual earnings (EBITDA): -276.74M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. XENE (627M). XENE has less debt than IDYA: XENE (9.02M) vs IDYA (26M). IDYA has higher revenues than XENE: IDYA (7M) vs XENE (0).
IDYAXENEIDYA / XENE
Capitalization1.85B2.36B78%
EBITDA-356.46M-276.74M129%
Gain YTD-17.899-22.29680%
P/E RatioN/AN/A-
Revenue7M0-
Total Cash693M627M111%
Total Debt26M9.02M288%
FUNDAMENTALS RATINGS
IDYA vs XENE: Fundamental Ratings
IDYA
XENE
OUTLOOK RATING
1..100
1660
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
6447
SMR RATING
1..100
4560
PRICE GROWTH RATING
1..100
6087
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is in the same range as XENE (76) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (47) in the Biotechnology industry is in the same range as IDYA (64) in the null industry. This means that XENE’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's SMR Rating (45) in the null industry is in the same range as XENE (60) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XENE’s over the last 12 months.

IDYA's Price Growth Rating (60) in the null industry is in the same range as XENE (87) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that XENE’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 15 days ago
77%
Bearish Trend 9 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IAMOX3.30N/A
N/A
Voya MidCap Opportunities Port A
SGIIX75.57N/A
N/A
First Eagle Global I
MGTSX39.45N/A
N/A
Morgan Stanley Inst Global Opp R6
WOOSX17.94N/A
N/A
JPMorgan SMID Cap Equity R6
SBRAX19.36N/A
N/A
Segall Bryant & Hamill All Cap Ret

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with CGON. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-2.50%
CGON - IDYA
60%
Loosely correlated
-0.78%
IMNM - IDYA
59%
Loosely correlated
-2.59%
CRNX - IDYA
56%
Loosely correlated
+0.78%
ETNB - IDYA
55%
Loosely correlated
-1.08%
XENE - IDYA
55%
Loosely correlated
-0.85%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with CRNX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-0.85%
CRNX - XENE
54%
Loosely correlated
+0.78%
ATXS - XENE
53%
Loosely correlated
+6.45%
IDYA - XENE
53%
Loosely correlated
-2.50%
KYMR - XENE
49%
Loosely correlated
+1.56%
RVMD - XENE
48%
Loosely correlated
-0.49%
More